No takes yet. Share an insight, caveat, or question.
Placebo-controlled trial demonstrates rituximab alters dominant B-cell receptor clones in individuals at risk of rheumatoid arthritis, suggesting transient depletion before memory cell emergence.
Musters et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: